Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31352065 | 0.98 | POLB (0.36) | POLBDRD2DRD4DRD3EGLN1 | |
| SCHEMBL5487170 | 0.82 | IRAK4 (0.35) | POLBALDH1A1PKM | |
| SCHEMBL4283522 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283523 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3MAPTHRH3 | |
| SCHEMBL2715907 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13603599 | 0.72 | DRD2 (0.46) | DRD2DRD4DRD3EGLN1HRH3 | |
| SCHEMBL22235731 | 0.70 | IRAK4 (0.42) | DRD2DRD4DRD3EGLN1AKT1 | |
| SCHEMBL27374106 | 0.70 | EGLN1 (0.44) | EGLN1AKT1 | |
| SCHEMBL23938200 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3EGLN1MAPT | |
| SCHEMBL3030761 | 0.68 | EGLN2 (0.50) | DRD2DRD4DRD3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676602-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024249817-A1 | TRICYCLIC PKMYT1 KINASE INHIBITORS | ENLIVEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024187153-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3990454-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020263980-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2019218024-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2019-11-21 | — | — | WO | disclosed |
| US-8076479-B2 | useful as cyclin-dependent kinase inhibitor compounds; minimizes the need for chromatographic purification of intermediates, and utilizes fewer changes of solvent systems | SCHERING CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011016559-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
| EP-2057166-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (3-ALKYL-5-PIPERIDIN-1-YL-3,3A-DIHYDRO- PYRAZOLOÝ1,5-A¨PYRIMIDIN-7-YL)-AMINO DERIVATIVES AND INTERMEDIATES | SCHERING CORPORATION (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027220-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (3-ALKYL-5-PIPERIDIN-1-YL-3, 3A-DIHYDROPYRAZOL0 [1, 5-A] PYRIMIDIN-7-YL) -AMINO DERIVATIVES | SCHERING CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058518-A1 | Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates | MERCK SHARP & DOHME LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1878734-A1 | NOVEL LACTAM COMPOUND | Ajinomoto Co., Inc. (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-7151109-B2 | Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1485384-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | Pharmacia & Upjohn Company LLC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | PHARMACIA & UPJOHN COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003078435-A1 | PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002511-A1 | Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators | CRHR1, HTR5A, CRH | POLB 4778/4885DRD2 145/4885DRD4 184/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | POLB 2188/4885DRD2 364/4885DRD4 897/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | POLB 3241/4885DRD2 4428/4885DRD4 3175/4885 |
| US-20080058518-A1 | Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates | CDK3, CDK7, CDK2 | POLB 373/4885DRD2 2013/4885DRD4 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.